Cocrystal Pharma, Inc.

NasdaqCM:COCP Rapporto sulle azioni

Cap. di mercato: US$17.6m

Cocrystal Pharma Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Cocrystal Pharma diminuiranno a una percentuale pari a 14.4% all'anno. Si prevede che l'EPS diminuirà a una percentuale pari a 14.7% all'anno.

Informazioni chiave

-14.4%

Tasso di crescita degli utili

-14.7%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.6%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento22 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19
We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19
Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06
We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05
We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13
Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24
What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20
Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:COCP - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026N/A-26N/AN/A1
12/31/2025N/A-23N/AN/A2
12/31/2024N/A-21N/AN/A3
6/30/2024N/A-18-14-14N/A
3/31/2024N/A-17-16-16N/A
12/31/2023N/A-18-15-15N/A
9/30/2023N/A-18-16-16N/A
6/30/2023N/A-20-23-22N/A
3/31/2023N/A-40-21-21N/A
12/31/2022N/A-39-22-21N/A
9/30/2022N/A-38-20-19N/A
6/30/2022N/A-36-16-16N/A
3/31/2022N/A-16-15-15N/A
12/31/2021N/A-14-13-13N/A
9/30/20211-12-12-12N/A
6/30/20211-11-10-10N/A
3/31/20212-10-10-9N/A
12/31/20202-10-10-10N/A
9/30/20202-56-9-9N/A
6/30/20202-55-7-7N/A
3/31/20202-53-6-6N/A
12/31/20197-48-2-2N/A
9/30/20196-45-2-2N/A
6/30/20196-45-3-3N/A
3/31/20195-45-4-4N/A
12/31/2018N/A-49-8-8N/A
9/30/2018N/A0-8-8N/A
6/30/2018N/A0-8-8N/A
3/31/2018N/A0N/A-7N/A
12/31/2017N/A-1N/A-7N/A
9/30/2017N/A-72N/A-8N/A
6/30/2017N/A-71N/A-9N/A
3/31/2017N/A-73N/A-13N/A
12/31/2016N/A-75N/A-15N/A
9/30/2016N/A-40N/A-15N/A
6/30/20160-38N/A-15N/A
3/31/20160-38N/A-13N/A
12/31/20150-50N/A-10N/A
9/30/20150-22N/A-9N/A
6/30/20150-24N/A-7N/A
3/31/20150-16N/A-6N/A
12/31/201400N/A-6N/A
9/30/2014N/A1N/A-5N/A
6/30/2014N/A3N/A-5N/A
3/31/2014N/A-3N/A-5N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che COCP rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che COCP rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che COCP rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di COCP cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Si prevede che COCP non avrà alcun fatturato il prossimo anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di COCP è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita